 OyaGen was founded on research conducted by Smith and Hui Zang, an HIV researcher at Thomas Jefferson University.OyaGen's research has focused on developing drug-based treatments for HIV and the company has three lead HIV drugs based upon editing enzymes in preclinical development.The company is exploring ways to prevent HIV from disabling the production of APOBEC3G (A3G), a naturally occurring editing enzyme that stops HIV from replicating.